US FDA Releases Draft Guidance to Accelerate Cell and Gene Therapy Development
The US FDA has issued draft guidance aimed at accelerating the development of cell and gene therapies by enabling sponsors to leverage existing scientific evidence, reduce redundant testing for treatments targeting rare and life-threatening diseases.
Gene Therapy Development | 04/06/2026 | By News Bureau
NanoMosaic Secures FDA AMT Designation for Nanoneedle Technology in AAV Gene Therapy Manufacturing
FDA’s CBER grants Advanced Manufacturing Technology designation to NanoMosaic’s Nanoneedle platform, enhancing regulatory engagement and streamlining quality control in AAV gene therapy production.
Gene Therapy Development | 30/01/2026 | By News Bureau | 132
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy